Bibliographic details

Younis T, Rayson D, Skedgel C.  The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Current Oncology 2011; 18(6): e288-e296


This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.

CRD summary

Indexing status

Subject indexing assigned by CRD

Index terms

Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; Humans; Markov Chains; Quality-Adjusted Life Years; Taxoids